Only a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer's disease.called lecanemab and aducanumab had received accelerated approval from the FDA. More recently, lecanemab, which has been shown to slow progression of the disease, has received traditional FDA approval.
"There is hope that these new therapies for Alzheimer's may slow progression of the disease for many people, although the fact remains that the drugs have only been studied in people with the earliest forms of the disease," said study author Maria Vassilaki, MD, Ph.D., of the Mayo Clinic in Rochester, Minnesota, and a member of the American Academy of Neurology.
"The inclusion and exclusion criteria of the clinical trials that led to FDA accelerated approval of these therapies form the basis of how people should be invited or discouraged from receiving one of these drugs. Our study estimates that only a small percentage of older people with early cognitive impairment due to Alzheimer's may be eligible to be treated with monoclonal antibodies for amyloid-ß in the brain.
The study included 237 people, ages 50 to 90, who had mild cognitive impairment or mild dementia, and whose
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Only a small percentage of older adults with early Alzheimer's eligible for new treatmentsOnly a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
Weiterlesen »
New study offers preliminary estimates of mortality risk by stage in Alzheimer's diseaseResearchers examine the expected survival of people at each stage of Alzheimer's disease.
Weiterlesen »
Charity art sale organiser shares heartbreaking story behind choosing Alzheimer's Society as beneficiaryOne of the organisers of a unique charity art sale has spoken of the devastating impact dementia has had on her family.
Weiterlesen »
Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s diseaseThe association between Androgen Deprivation Therapy (ADT) and the risk of dementia.
Weiterlesen »
Several vaccines associated with reduced risk of Alzheimer's disease in adults 65 and olderPrior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer's disease, according to new research from UTHealth Houston.
Weiterlesen »
Multimodal intervention approach shows promise in managing and reversing cognitive impairmentDr. Heather Sandison, a leading expert in Alzheimer's Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer's Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline.
Weiterlesen »